
The U.S. @FDA has approved a supplemental New Drug Application updating the U.S. Prescribing Information for our approved cardiac myosin inhibitor. The update includes data from MAPLE-HCM, a Phase 3 trial in adults with symptomatic oHCM. bit.ly/4jiBzfY







